These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 29679606)

  • 21. Drug Repurposing of Generic Drugs: Challenges and the Potential Role for Government.
    van der Pol KH; Aljofan M; Blin O; Cornel JH; Rongen GA; Woestelandt AG; Spedding M
    Appl Health Econ Health Policy; 2023 Nov; 21(6):831-840. PubMed ID: 37398987
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Repurposing drug molecules for new pulmonary therapeutic interventions.
    Mehta PP; Dhapte-Pawar VS
    Drug Deliv Transl Res; 2021 Oct; 11(5):1829-1848. PubMed ID: 33188495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Industry guidance for the selection of a delivery system for the development of novel respiratory products.
    Pritchard JN
    Expert Opin Drug Deliv; 2015; 12(11):1755-65. PubMed ID: 26067581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repurposing and repositioning neurosteroids in the treatment of traumatic brain injury: A report from the trenches.
    Stein DG; Sayeed I
    Neuropharmacology; 2019 Mar; 147():66-73. PubMed ID: 29630902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Repurposed drugs in metabolic disorders.
    Finsterer J; Frank M
    Curr Top Med Chem; 2013; 13(18):2386-94. PubMed ID: 24059459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Repurposing of parenterally administered active substances used to treat pain both systemically and locally.
    Battaglia LS; Dorati R; Maestrelli F; Conti B; Gabriele M; Di Cesare Mannelli L; Selmin F; Cosco D
    Drug Discov Today; 2022 Oct; 27(10):103321. PubMed ID: 35850432
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lessons from innovation in drug-device combination products.
    Couto DS; Perez-Breva L; Saraiva P; Cooney CL
    Adv Drug Deliv Rev; 2012 Jan; 64(1):69-77. PubMed ID: 22200650
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The potential to treat lung cancer via inhalation of repurposed drugs.
    Lee WH; Loo CY; Ghadiri M; Leong CR; Young PM; Traini D
    Adv Drug Deliv Rev; 2018 Aug; 133():107-130. PubMed ID: 30189271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Challenges and Benefits of Repurposing Licensed/Approved/Cleared Products for a Radiation Indication.
    Price PW; DiCarlo AL
    Radiat Res; 2018 Dec; 190(6):654-658. PubMed ID: 30281977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Challenges and opportunities of drug repositioning.
    Novac N
    Trends Pharmacol Sci; 2013 May; 34(5):267-72. PubMed ID: 23582281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The drug repurposing landscape from 2012 to 2017: evolution, challenges, and possible solutions.
    Polamreddy P; Gattu N
    Drug Discov Today; 2019 Mar; 24(3):789-795. PubMed ID: 30513339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bleomycin--electrical pulse delivery: electroporation therapy-bleomycin--Genetronics; MedPulser-bleomycin--Genetronics.
    Drugs R D; 2004; 5(5):293-6. PubMed ID: 15357628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bringing smart pills to market: FDA regulation of ingestible drug/device combination products.
    Avery M; Liu D
    Food Drug Law J; 2011; 66(3):329-52, i. PubMed ID: 24505852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Delivery Systems as Vital Tools in Drug Repurposing.
    Czech T; Lalani R; Oyewumi MO
    AAPS PharmSciTech; 2019 Feb; 20(3):116. PubMed ID: 30771030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Challenges in inhaled product development and opportunities for open innovation.
    Forbes B; Asgharian B; Dailey LA; Ferguson D; Gerde P; Gumbleton M; Gustavsson L; Hardy C; Hassall D; Jones R; Lock R; Maas J; McGovern T; Pitcairn GR; Somers G; Wolff RK
    Adv Drug Deliv Rev; 2011; 63(1-2):69-87. PubMed ID: 21144875
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Repurposing available drugs for neurodevelopmental disorders: The fragile X experience.
    Tranfaglia MR; Thibodeaux C; Mason DJ; Brown D; Roberts I; Smith R; Guilliams T; Cogram P
    Neuropharmacology; 2019 Mar; 147():74-86. PubMed ID: 29792283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements.
    Wallach JD; Ross JS; Naci H
    Clin Trials; 2018 Jun; 15(3):219-229. PubMed ID: 29871509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.